Site icon pharmaceutical daily

Hospital Acquired Pneumonia (HAP) Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hospital
Acquired Pneumonia (HAP) – Pipeline Review, H1 2019”
drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

This latest Pharmaceutical and Healthcare disease pipeline guide
Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2019, provides
an overview of the Hospital Acquired Pneumonia (HAP) (Infectious
Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired
during hospital stay. Symptoms include cough, fever, shaking chills,
confusion, headache and loss of appetite. Risk factors include chronic
lung disease, cigarette smoking, dementia, stroke, brain injury, heart
disease, liver cirrhosis and diabetes mellitus. Treatment includes
antibiotics and healthy lifestyle.

This latest pipeline guide provides comprehensive information on the
therapeutics under development for Hospital Acquired Pneumonia (HAP)
(Infectious Disease), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline
guide also reviews of key players involved in therapeutic development
for Hospital Acquired Pneumonia (HAP) and features dormant and
discontinued projects. The guide covers therapeutics under Development
by Companies /Universities /Institutes, the molecules developed by
Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and
Unknown stages are 8, 5, 10, 10, 2 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide
helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage. The
guide is built using data and information sourced from the researcher’s
proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured
on a real time basis.

Scope

Reasons to buy

Key Topics Covered:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m7q93l

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs
, Infectious
Diseases Drugs

Exit mobile version